Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Kinrix Co-administered with Varivax and MMR
NCT00871117Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2009
- Primary completion
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) in diphtheria, Tetanus, pertussis and 1 more (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Booster Responses to Diphtheria and Tetanus at 1 month, Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (FHA) and Anti-pertactin (Anti-PRN) Booster Responses at 1 month and 1 more. Started Mar 2009; status: completed.
02
Drugs
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
03
Conditions
diphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on NCT00871117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00871117.